Catalio Capital Targets $500 Million Fund for AI Healthcare Startups — Research Library

Key Highlights

Catalio Capital Management is reportedly seeking $500 million for a fund targeting startups combining artificial intelligence with healthcare.
That would be the New York firm's second fundraise in roughly 16 months, after Nexus Fund IV closed above $400 million and a life sciences private credit vehicle exceeded $325 million.
Catalio manages roughly $2 billion and in September 2026 led a $311 million Series E round for AI-enabled drug discovery company Enveda Therapeutics.

Context and Core Dynamics

Catalio Capital Management, a New York investment firm founded in 2020, is seeking $500 million for a vehicle dedicated to companies where artificial intelligence meets healthcare; KKR & Co. has held a partial stake since 2023. Reported on 15 October 2026, the effort remains in progress; final size could change before any close. This would be its second fundraise in roughly 16 months. In mid-2025, Catalio closed Catalio Nexus Fund IV above $400 million, ahead of its original target, and in early 2026 raised over $325 million for a life sciences private credit vehicle that was oversubscribed and beat its initial goal. The firm reports more than 20 exits since launching. Co-founders George Petrocheilos and R. Jacob Vogelstein, Ph.D.; advisory board includes KKR co-founder Henry Kravis as co-chairman and former Johnson & Johnson chief executive Alex Gorsky.

Its thesis treats artificial intelligence and biomedicine as interdependent, directing capital toward companies that blend AI with biomedicine and clinical care and aiming to build category-defining businesses. In September 2026, Catalio led a $311 million Series E round for Enveda Therapeutics, doubling its valuation to approximately $2 billion. Enveda works in AI-enabled drug discovery, where software helps scientists search for promising molecules faster.

Caregiving Application and Social Impact

Such platforms sit upstream of caregiving but shape it: compressed discovery timelines can widen the therapeutic pipeline for conditions dominating later life, altering what rehabilitation and long-term support can attempt. Related methods underpin clinical decision support, medication reconciliation and risk stratification in geriatric and specialised care, potentially reducing administrative load and extending scarce specialist expertise.

The open question is distribution: capability concentrated in well-resourced institutions leaves neediest caregivers unserved, and investment volume alone does not resolve that. Reimbursement structures, interoperability and workforce training determine whether tools reach older adults.

Ethics and Compliance Note

AI in health and caregiving has established boundaries. Clinical and genomic data used to train models are sensitive, so consent, de-identification and jurisdictional data protection rules must govern collection and reuse. Predictive tools can encode bias against older adults where training cohorts are unrepresentative, and opaque recommendations can erode the autonomy of the person receiving care. Oversight should require prospective validation, documented performance across age and demographic groups, and human accountability for consequential decisions. The International AI Caregiving Association (IAICA) holds that deployment in care settings remains subordinate to clinical judgement and to the individual's expressed preferences.